Stefano Luminari, MD, details the safety profile of odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.
Stefano Luminari, MD
Advertisement
Stefano Luminari, MD, is an associate professor of Oncology at the University of Modena and Reggio Emilia in Italy.
Articles by Stefano Luminari, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5